OBJECTIVE: To describe a unique case of secondary gliosarcoma (SGS) with widespread extra-cranial metastases that developed more than 5 years after the initial diagnosis of glioblastoma multiforme (GBM). This interval is the longest among the cases reported to date. METHODS: A PUBMED search using the key words "secondary gliosarcoma" and "extra-cranial metastases" was performed followed by a review of cited literature. RESULTS: Including our report, we found 44 cases of SGS, of which only 5 developed extra-cranial metastases. CONCLUSION: SGS with extra-cranial metastases is extremely rare. Of previously reported cases, the longest survival was 2 months after the diagnosis of SGS. The present case had a survival of 6.5 months. Our case highlights the importance of screening for extra-cranial metastases in SGS. The optimal treatment of SGS is not known and strategies based on GBM and sarcoma treatments have been employed with limited success. A combination of treatment modalities may extend survival as in the present report; however the prognosis remains poor.
OBJECTIVE: To describe a unique case of secondary gliosarcoma (SGS) with widespread extra-cranial metastases that developed more than 5 years after the initial diagnosis of glioblastoma multiforme (GBM). This interval is the longest among the cases reported to date. METHODS: A PUBMED search using the key words "secondary gliosarcoma" and "extra-cranial metastases" was performed followed by a review of cited literature. RESULTS: Including our report, we found 44 cases of SGS, of which only 5 developed extra-cranial metastases. CONCLUSION:SGS with extra-cranial metastases is extremely rare. Of previously reported cases, the longest survival was 2 months after the diagnosis of SGS. The present case had a survival of 6.5 months. Our case highlights the importance of screening for extra-cranial metastases in SGS. The optimal treatment of SGS is not known and strategies based on GBM and sarcoma treatments have been employed with limited success. A combination of treatment modalities may extend survival as in the present report; however the prognosis remains poor.
Authors: Johan M Kros; Dana M Mustafa; Lennard J M Dekker; Peter A E Sillevis Smitt; Theo M Luider; Ping-Pin Zheng Journal: Neuro Oncol Date: 2014-09-24 Impact factor: 12.300
Authors: Alfredo E Romero-Rojas; Julio A Diaz-Perez; Lina M Ariza-Serrano; Deirdre Amaro; Alfonso Lozano-Castillo Journal: Neuroradiol J Date: 2013-12-18
Authors: Kevin J Anderson; Aaron C Tan; Jonathon Parkinson; Michael Back; Marina Kastelan; Allison Newey; Janice Brewer; Helen Wheeler; Amanda L Hudson; Samirkumar B Amin; Kevin C Johnson; Floris P Barthel; Roel G W Verhaak; Mustafa Khasraw Journal: Cold Spring Harb Mol Case Stud Date: 2020-02-03